-
1 Comment
NexgenRx Inc is currently in a long term uptrend where the price is trading 23.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.3.
NexgenRx Inc's total revenue rose by 3.6% to $3M since the same quarter in the previous year.
Its net income has increased by 918.9% to $510K since the same quarter in the previous year.
Finally, its free cash flow grew by 329.6% to $909K since the same quarter in the previous year.
Based on the above factors, NexgenRx Inc gets an overall score of 5/5.
| Exchange | V |
|---|---|
| CurrencyCode | CAD |
| Sector | Healthcare |
| Industry | Healthcare Plans |
| ISIN | CA65337X1042 |
| PE Ratio | 0.0 |
|---|---|
| Beta | 0.53 |
| Market Cap | 21M |
| Dividend Yield | 3.5% |
| Target Price | 4.25 |
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. The company also provides ancillary services. TNexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NXG.V using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
